$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Dexcom is valued at $30.72B on its latest close. Its price is 31.0 times its earnings.
| Market value | $30.72B |
|---|
| Enterprise value | $31.46B |
|---|
| Price / earnings | 31.00 |
|---|
| Price / sales | 6.02 |
|---|
| Price / book | 12.12 |
|---|
| EV / EBITDA | 20.99 |
|---|
| EV / sales | 6.16 |
|---|
| Price / free cash flow | 27.97 |
|---|
| Price / free cash flow, own 5-year average | 127.48 |
|---|
| EV / EBIT | 25.41 |
|---|
| EV / free cash flow | 28.31 |
|---|
| Free cash flow yield | 3.6% |
|---|
Share price
| Latest close | $83.33 |
|---|
| Day's change | +2.4% |
|---|
| 52-week high | $92.59 |
|---|
| 52-week low | $56.72 |
|---|
| From 52-week high | −10.0% |
|---|
| Return · 1 month | −3.1% |
|---|
| Return · 3 months | −7.6% |
|---|
| Return · year to date | +25.6% |
|---|
| Return · 1 year | +39.8% |
|---|
| Beta · 1 year against the S&P 500 | 0.69 |
|---|
| 50-day average | $84.30 |
|---|
| 200-day average | $75.08 |
|---|
| RSI 14 | 51.4 |
|---|
| Average volume · 20 sessions | 5.0M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 60.1% |
|---|
| Operating margin | 19.6% |
|---|
| Net margin | 17.9% |
|---|
| Free cash flow margin | 23.1% |
|---|
| Return on equity | 34.5% |
|---|
| Return on assets | 10.9% |
|---|
| Return on invested capital | 20.8% |
|---|
| Return on invested capital, 5-year average | 16.8% |
|---|
| Return on capital employed | 23.5% |
|---|
| Stock-based compensation / revenue | 3.4% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $917.7M |
|---|
| Total debt | $1.34B |
|---|
| Net debt | $418.2M |
|---|
| Current ratio | 1.88 |
|---|
| Quick ratio | 0.95 |
|---|
| Debt / equity | 0.49 |
|---|
| Net debt / EBITDA | 0.36 |
|---|
| Interest coverage | 63.76 |
|---|
Growth
| Revenue, latest quarter on a year | +11.2% |
|---|
| Revenue, twelve months on a year | +13.0% |
|---|
| EPS, latest quarter on a year | +2.9% |
|---|
| EPS, twelve months on a year | +43.1% |
|---|
| Revenue, 5-year compound | +19.3% |
|---|
| Revenue, 10-year compound | +27.8% |
|---|
| Net income, 5-year compound | +8.8% |
|---|
| Free cash flow, 5-year compound | +31.3% |
|---|
| EPS, 5-year compound | +9.5% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 406M |
|---|
| Shares outstanding, 5-year compound | −0.7% |
|---|
| Net share repurchases | $471.9M |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $252.1M |
|---|
| Effective tax rate | 23.2% |
|---|
DXCM in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.